# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Clear Street analyst Bill Maughan initiates coverage on WAVE Life Sciences (NASDAQ:WVE) with a Buy rating and announces Pric...
Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight and lowers the price target from...
Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production a...
HC Wainwright & Co. analyst Andrew S. Fein reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $22 price...